%0 Journal Article
%T DS-8201a治疗HER2表达实体肿瘤的研究进展<br>Research Progress of DS-8201a in the Treat-ment of HER2-Expressing Solid Tumors
%A 王宁
%A 岳麓
%J Advances in Clinical Medicine
%P 7611-7618
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.1351063
%X 在精准治疗背景下，针对各种肿瘤驱动基因的靶向治疗极大地改变了当今的治疗现状。表皮生长因子受体2 (Human Epidermal Growth Factor Receptor 2; HER2)是多种肿瘤的驱动基因，DS-8201a (Trastuzumab deruxtecan; T-Dxd)作为一种新型靶向HER2的抗体偶联药物(Antibody-Drug Conju-gates; ADC)，不仅对HER2过表达的肿瘤具有抗肿瘤作用，而且对于HER2低表达、扩增及突变患者也具有不错的疗效。目前DS-8201a已经在多种实体瘤中进行了广泛的临床研究。本文概述了DS-8201a的结构和作用特点，并介绍其在各种实体肿瘤中的研究进展，为未来的精准靶向治疗提供方向。<br />
In the context of precision therapy, targeted therapy for various tumor driver genes has greatly changed the current therapeutic status. The epidermal growth factor receptor 2 (HER2) is a wide variety of tumor driver gene, DS-8201a (Trastuzumab deruxtecan; T-Dxd; Enhertu) as a novel HER2-targeting Antibody-drug conjugates (ADC), not only has antitumor effect on tumors with overexpression of HER2, but also has efficacy in patients with low expression, amplification and mutation of HER2. DS-8201a has been extensively tested in clinical trials in a variety of solid tumors. This article summarizes the structure and functional characteristics of DS-8201a, and introduces its research progress in various solid tumors, and provides directions for future precise targeted therapy.
%K DS-8201a，HER2，乳腺癌，胃癌<br>DS-8201a
%K HER2
%K Breast Cancer
%K Gastric Cancer
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=65305